Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum?
Investors will focus on lead drug Cabometyx's performance when Exelixis EXEL reports first-quarter 2025 results shortly.
The Zacks Consensus Estimate for sales and earnings is pegged at $502.8 million and 42 cents per share, respectively. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Exelixis' Earnings Surprise History
Exelixis beat on earnings in three of the trailing four quarters and missed in the remaining one, the average surprise being 26.87%. In the last reported quarter, the company beat on earnings by 7.84%.
Factors at Play in Q1
Exelixis generates revenues from net product sales, license revenues and collaboration and service revenues.
Net product revenues have likely increased in the first quarter, driven by a rise in Cabometyx sales volumes and average net selling price.
Cabometyx is approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma. The drug maintains its status as the leading TKI for RCC, both in the front-line IO+TKI market and the second-line monotherapy segment. The trend is likely to have continued in the first quarter.
The Zacks Consensus Estimate for sales of the drug is pegged at $434 million and our model estimate for the same is pinned at $457.3 million.
Collaboration revenues increased in the previous quarter on higher royalty revenues for the sales of cabozantinib outside of the United States generated by collaboration partners, Ipsen Pharma SAS and Takeda Pharmaceutical Company Limited. The trend is likely to have continued in the to-be-reported quarter.
Last month, the FDA approved the label expansion of Cabometyx for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET).
Simultaneously, the drug was approved for adult and pediatric patients (12 years of age and older) with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET (epNET). Additional updates on the same are expected.
The board recently authorized the repurchase of up to an additional $500 million of the company's common stock before Dec. 31, 2025. Exelixis plans to complete the currently ongoing $500 million stock repurchase program (announced in August 2024) in the second quarter of 2025 and commence repurchases under the newly authorized program thereafter.
The bottom line has likely gained from the ongoing share repurchases.Operating expenses might have increased due to costs associated with the broader portfolio.
What Our Model Predicts for EXEL
Our proven model predicts an earnings beat for EXEL this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. This is the case here, as you will see below.
Earnings ESP: Earnings ESP for Exelixis is +7.14% as the Zacks Consensus Estimate is pegged at 42 cents per share, while the Most Accurate Estimate is pinned at 45 cents per share. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3.
Exelixis Price Performance
The company's shares have gained 11.4% year to date against the industry 's decline of 3.7%.
Stocks to Consider
Here are some stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this reporting cycle.
argenx ARGX has an Earnings ESP of +10.92% and a Zacks Rank #2 at present. You can see the complete list of today's Zacks #1 Rank stocks here.
ARGX beat on earnings in two of the last four quarters and missed in the other two, delivering an average surprise of 345.11%.
Vertex Pharmaceuticals VRTX has an Earnings ESP of +0.40% and a Zacks Rank #3 at present.
VRTX beat on earnings in two of the trailing four quarters and missed in the remaining two, the average surprise being 2.58%. The company will report first-quarter results on May 5, 2025.
AstraZeneca AZN has an Earnings ESP of +2.73% and a Zacks Rank #3 at present.
AZN is scheduled to release first-quarter results on April 29, 2025. AstraZeneca beat on earnings in three of the trailing four quarters and missed in the remaining one, the average surprise being 3.16%.
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AstraZeneca PLC (AZN): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Exelixis, Inc. (EXEL): Free Stock Analysis Report
argenex SE (ARGX): Free Stock Analysis Report
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
5 days ago
- Globe and Mail
Buy, Hold or Sell Dollar General? Key Tips Ahead of Q1 Earnings
As Dollar General Corporation DG prepares to release its first-quarter fiscal 2025 earnings results on June 3, before the opening bell, investors face a critical decision: Is now the time to buy, hold or sell the stock? The impending report could be a turning point, offering insight into whether the discount retailer's turnaround strategy is gaining traction. DG is likely to have registered an increase in the top line. The Zacks Consensus Estimate for revenues is pegged at $10.29 billion, which indicates an improvement of 3.8% from the prior-year reported figure. However, the company is expected to have witnessed a year-over-year decrease in its bottom line. Although the Zacks Consensus Estimate has increased by a penny over the past 30 days to $1.47 per share, it still suggests a decline of 10.9% from the year-ago period. Dollar General has a trailing four-quarter negative earnings surprise of 1.2%, on average. In the last reported quarter, the company's bottom line beat the Zacks Consensus Estimate by a margin of 12%. (See the Zacks Earnings Calendar to stay ahead of market-making news.) Dollar General Corporation Price, Consensus and EPS Surprise Dollar General Corporation price-consensus-eps-surprise-chart | Dollar General Corporation Quote What the Zacks Model Predicts for DG As investors prepare for Dollar General's first-quarter announcement, the question looms regarding earnings beat or miss. Our proven model predicts that an earnings beat is likely for Dollar General this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is the case here. You can see the complete list of today's Zacks #1 Rank stocks here. Dollar General has an Earnings ESP of +2.64% and carries a Zacks Rank #3. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Factors to Note Ahead of DG's Q1 Earnings Dollar General's strategic push to grow its market share in the consumables and non-consumables categories underscores its competitive pricing and strong value proposition, which resonate well with budget-conscious consumers. Proactive pricing strategies, targeted promotions and the ongoing expansion of private-label offerings are expected to have supported top-line growth. We remain optimistic about several key initiatives, including DG Fresh, SKU rationalization, digitization and the expansion of the private fleet, which are likely to have contributed to improvements in same-store sales. The company's 'back-to-basics' approach has helped reinforce operational discipline, while efforts to reduce shrinkage are already delivering measurable gains. For the quarter under review, we project a 0.8% increase in same-store sales. The same-day delivery pilot program is expected to have driven incremental sales by providing additional convenience for shoppers. Furthermore, the company's partnership with DoorDash is likely to have helped capture digital sales. These factors, combined with increased foot traffic, are expected to have boosted revenues in the quarter. Despite these strategic moves, Dollar General guided a challenging first half of fiscal 2025 due to upfront costs associated with remodeling projects and increased labor-related expenses. Management projected earnings per share (EPS) to decline on a year-over-year basis during this period. We expect SG&A expenses, as a percentage of net sales, to deleverage 90 basis points. As a result, we foresee an operating margin contraction of 70 basis points. Dollar General Stock Performance Shares of Dollar General have rallied 35.3% over the past three months, outperforming the industry's 0.2% growth. The stock has also outpaced key competitors, including Dollar Tree, Inc. DLTR, Target Corporation TGT and Costco Wholesale Corporation COST. While Dollar Tree has seen a gain of 31.2%, Costco and Target have declined 0.6% and 22.2% during the same period. Does DG Present a Strong Case for Value Investing? Dollar General is currently trading at a forward 12-month price-to-earnings (P/E) ratio of 16.84. This valuation reflects a discount compared to the industry's average of 33.73 and the S&P 500's P/E of 21.71. However, the stock appears overvalued compared to its median P/E level of 13.62, observed over the past year. Dollar General is trading at a premium to Target (with a forward 12-month P/E ratio of 12.03) and Dollar Tree (16.71) but at a discount to Costco (53.65). How to Play Dollar General Stock Now: Buy, Hold or Sell? Given the ongoing turnaround efforts and encouraging early signs of operational discipline, Dollar General seems to be on the right track, though challenges remain. While near-term margin pressures and earnings pressure necessitate caution, the underlying fundamentals and strategic initiatives indicate potential for gradual recovery. For now, current investors may consider holding the stock, meanwhile, potential investors may wait for stronger evidence of margin stabilization before initiating a position. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Target Corporation (TGT): Free Stock Analysis Report Dollar General Corporation (DG): Free Stock Analysis Report Dollar Tree, Inc. (DLTR): Free Stock Analysis Report Costco Wholesale Corporation (COST): Free Stock Analysis Report
Globe and Mail
30-05-2025
- Globe and Mail
2 Top Stocks to Buy With Less Than $100
When investing on a budget, buying fractional shares of top companies is one option. Another is to find stocks with relatively affordable price tags per share. Although it's sometimes the case that the most attractive companies quickly draw attention, which bids up their share prices, it's still possible to find promising stocks for well under $100. Two great options right now are Novo Nordisk (NYSE: NVO) and Exelixis (NASDAQ: EXEL). Here's why these healthcare companies are worth investing in today. 1. Novo Nordisk Novo Nordisk had been flying high since the beginning of the decade, until it ran into significant clinical and regulatory headwinds last year. Its challenges eventually came to a boiling point and the company parted ways with its longtime CEO, Lars Fruergaard Jørgensen, a decision it announced in mid-May. It's worth noting that Jørgensen led Novo Nordisk through a period of rapid clinical advancements, particularly within its GLP-1 segment. Novo Nordisk's top medicines, Wegovy for weight management and Ozempic for diabetes, continue to deliver excellent results. Jørgensen leaves a solid foundation for the next head of the company to build upon. Given Novo Nordisk's lineup, pipeline, and track record, the stock is likely to recover eventually. Here's one reason why. Despite recent challenges, Novo Nordisk's revenue continues to grow faster than that of almost every similarly sized pharmaceutical company. In the first quarter, net sales totaled 78.1 billion Danish kroner ($11.9 billion), a 19% increase compared to the same period last year. And on the bottom line, earnings per share were 6.53 DKK ($1), up 15% year over year. Meanwhile, Novo Nordisk should continue making moves to remain competitive in the fast-growing anti-obesity market, despite incurring some losses recently to its biggest rival, Eli Lilly. Novo Nordisk recently submitted an application to U.S. regulators requesting approval for an oral version of semaglutide, the active ingredient in Wegovy and Ozempic. Current GLP-1 therapies are typically administered by injection. Novo Nordisk also has several early-stage assets in this field, including a potential triple agonist -- a GLP-1 medicine that also mimics the action of two other gut hormones. Elsewhere, the FDA (U.S. Food and Drug Administration) accepted the company's regulatory application for Wegovy in treating metabolic dysfunction-associated steatohepatitis (MASH) and granted it priority review; it's also under review by regulatory authorities for this indication in Europe. There is only one FDA-approved medicine for MASH, despite the millions of patients affected and the condition's growing prevalence. Lastly, Novo Nordisk is making progress across its pipeline, including in other therapeutic areas, such as Alzheimer's disease, where it has upcoming data readouts. Recent headwinds notwithstanding, the company remains well- positioned to lead in diabetes and obesity care for the long term, while also making strides in other areas. The stock could still deliver superior returns to patient investors. And with shares trading for just under $71 each, $100 can get you one of them. 2. Exelixis Exelixis is an oncology specialist; its most important medicine, Cabometyx, treats some forms of liver and kidney cancer. Some investors have long been worried about Exelixis' overreliance on this drug, and with good reason. In the first quarter, Exelixis' revenue came in at $555.4 million, up 30% year over year; Cabometyx's sales came in at $510.9 million. If something were to happen to this medicine -- like generic competition -- it would be a disaster for the company. Fortunately, Exelixis fended off this threat last year with a significant win in a legal battle against a generic-drug manufacturer, which should keep its cheaper competitor off the market until 2030. Still, Exelixis has continued to grind out indications for its crown jewel. One of the latest was in treating metastatic, well-differentiated pancreatic neuroendocrine tumors, a nod it received in March. Cabometyx has long been one of the top-prescribed cancer medicines of its kind in renal cell carcinoma (kidney cancer), and additional indications have helped it continue to grow its sales. Exelixis should maintain that momentum through the end of the decade. Meanwhile, it's developing other cancer medicines. It tends to target areas of the field with high unmet need, such as metastatic colorectal cancer. Despite being the second leading cause of cancer death worldwide, colorectal cancer is highly treatable when caught early -- but once it has metastasized, five-year survival rates drop. Exelixis is developing zanzalintinib to address this problem. The medicine is being tested in other clinical trials as well. Exelixis' revenue and earnings should maintain a solid upward trajectory as it secures more clinical and regulatory wins. That's how the stock can deliver strong returns. Shares are trading for about $43, so you can grab two of them with $100. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,761!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $826,263!* Now, it's worth noting Stock Advisor 's total average return is978% — a market-crushing outperformance compared to170%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of May 19, 2025
Globe and Mail
29-05-2025
- Globe and Mail
Analyzing the Current Earnings Outlook
Note: The following is an excerpt from this week's Earnings Trends report. You can access the full report that contains detailed historical actual and estimates for the current and following periods, please click here>>> Here are the key points: Total S&P 500 earnings for the June quarter are expected to be up +5.5% from the same period last year on +3.8% higher revenues, with a broader and greater pressure on estimates relative to other recent periods. Q2 earnings estimates for 15 of the 16 Zacks sectors are down since the quarter got underway, with Aerospace as the only sector whose estimates have moved higher. The Tech sector's estimates are down since the start of the period, but they have notably stabilized in recent weeks. The Q1 reporting cycle is now effectively behind us, with results from less than two dozen S&P 500 members still awaited at this stage. The Q1 earnings cycle has ended for 9 of the 16 Zacks sectors. Total Q1 earnings for the 477 S&P 500 members that have reported results are up +11.4% from the same period last year on +4.4% higher revenues, with 74.2% beating EPS estimates and 62.9% beating revenue estimates. An Underwhelming Retail Sector Earnings Performance Total Q1 earnings for the 28 of the 33 Retail sector companies in the S&P 500 index that have reported already are up +11.2% from the same period last year on +5.0% higher revenues, with 60.7% beating EPS estimates and 57.1% beating revenue estimates. Regular users of Zacks Research know that we have a stand-alone economic sector for the Retail sector, unlike the 'official' Standard & Poor's classification that places retailers in the Consumer Discretionary and Consumer Staples sectors. The Zacks Retail sector includes online vendors like Amazon AMZN, restaurant operators like McDonald's MCD, and conventional retailers like Walmart WMT and Target TGT. The comparison charts below show the Q1 EPS and revenue beats percentages for these companies in the context of what we had seen from the same group of 28 Retail sector companies in other recent periods. As you can see above, these Retail sector companies have been struggling to beat EPS and revenue estimates. The comparison charts below show this group's earnings and revenue growth rates in a historical context. The right-hand chart shows the group's earnings and revenue growth pace on an ex-Amazon basis. As you can see below, the group's +11.2% earnings growth drops to a decline of -5.0% once Amazon's substantial contribution is excluded from the numbers. If we look at Retail sector earnings on an annual basis, the expectation is for +4.1% earnings growth this year, which follows +22.7% growth in 2024. But as we saw with the Q1 earnings results, all of that growth is coming from Amazon, with this year's +4.1% earnings growth dropping to -0.6% and last year's +22.7% dropping to +1.8% once Amazon's contribution is excluded from the sector's numbers. A significant part of the sector's earnings challenge is a result of margin pressures, with the logistics associated with e-commerce sales forcing retailers to spend heavily on fulfillment and deliveries. You can see this in the chart below that shows the sector's net margins on an annual basis. The left-hand side showing the sector as a whole and the right-hand side showing the sector's margins excluding Amazon. As you can see above, Retail sector margins outside of Amazon have been on a downtrend since 2021, with this year's margins expected to serve as a bottom and start recovering going forward. Evolving Expectations for 2024 Q2 and Beyond The start of Q2 coincided with heightened tariff uncertainty following the punitive April 2 nd tariff announcements. While the onset of the announced levies was eventually delayed for three months, the issue has understandably weighed heavily on estimates for the current and coming quarters. The expectation at present is for Q2 earnings for the S&P 500 index to increase by +5.5% from the same period last year on +3.8% higher revenues. The chart below shows how Q2 earnings growth expectations have evolved since the start of the year. While it is not unusual for estimates to be adjusted lower, the magnitude and breadth of Q2 estimate cuts are greater than we have seen in the comparable periods of other recent quarters. Since the start of the quarter, estimates have come down for 15 of the 16 Zacks sectors, with the biggest declines for the Transportation, Autos, Energy, Construction, and Basic Materials sectors. The only sector experiencing favorable revisions in this period is Aerospace. Estimates for the two largest earnings contributors to the index – Tech & Finance – have also declined since the quarter began. Tech sector earnings are expected to be up +11.9% in Q2 on +9.9% higher revenues. While these earnings growth expectations are materially below where they stood at the start of April, the revisions trend appears to have notably stabilized lately, as we have been flagging in recent weeks. You can see this in the sector's revisions trend in the chart below. This stabilizing turn in the Tech sector's revisions trend can be seen in expectations for full-year 2025 as well, as the chart below shows. The above two charts show that estimates for the Tech sector have stabilized and are no longer under the type of downward pressure that we were experiencing earlier. The Tech sector is much more than just any another sector, as it alone accounts for almost a third of all S&P 500 earnings. The Earnings Big Picture The chart below shows expectations for 2025 Q1 in terms of what was achieved in the preceding four periods and what is currently expected for the next four quarters. Image Source: Zacks Investment Research The chart below shows the overall earnings picture for the S&P 500 index on an annual basis. While estimates for this year have been under pressure lately, there haven't been a lot of changes to estimates for the next two years at this stage. Stocks have recouped their tariff-centric losses, although the issue has only been deferred for now. While some of the more dire economic projections have eased lately, there is still plenty of macro uncertainty that will likely continue to weigh on earnings estimates in the days ahead, particularly as we gain visibility on the tariffs question. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Inc. (AMZN): Free Stock Analysis Report Target Corporation (TGT): Free Stock Analysis Report Walmart Inc. (WMT): Free Stock Analysis Report McDonald's Corporation (MCD): Free Stock Analysis Report
